TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19339045

Group type: EXPERIMENTAL
Intervention: Polycap (low doses of thiazide 12.5 mg, atenolol 50 mg, ramipril 5 mg, simvastatin 20 mg, and aspirin 100 mg per day)
Number of subjects: 2053

Group type: EXPERIMENTAL
Intervention: Polycap
Number of subjects: 2053

Group type: EXPERIMENTAL
Intervention: Polycap and other groups using atenolol
Number of subjects: 2053
Study: 16987908

Group type: EXPERIMENTAL
Intervention: Epoetin-beta 36,000 IU
Number of subjects: 86

Group type: COMPARATOR
Intervention: Epoetin-beta 9000 IU
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Epoetin-beta (all dosage groups)
Number of subjects: 86
Study: 12810937

Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg daily
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg daily
Number of subjects: 722

Group type: COMPARATOR
Intervention: Diclofenac 75 mg slow release twice daily
Number of subjects: 722
Study: 10671912

Group type: EXPERIMENTAL
Intervention: Active group (clinical pharmacist visit and best practice chart)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no visit, no chart)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 9020593

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 30
Study: 1532072

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 100
Study: 6540047

Group type: EXPERIMENTAL
Intervention: 400 kcal soy protein
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 kcal collagen protein
Number of subjects: 30

Group type: COMPARATOR
Intervention: Total fasting with potassium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Total fasting without potassium
Number of subjects: 30
Study: 30843245

Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg
Number of subjects: 302

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 302
Study: 29950182

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g single dose, administered 1 day before surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (single dose, administered 1 day before surgery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25582793

Group type: EXPERIMENTAL
Intervention: M. tuberculosis bacteremia
Number of subjects: 90
Study: 24163988

Group type: EXPERIMENTAL
Intervention: Moisturizer containing licochalcone A (LicA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 1% hydrocortisone
Number of subjects: 55
Study: 22155918

Group type: EXPERIMENTAL
Intervention: HIV RNA >5 log(10) copies/ml
Number of subjects: 274
Study: 19109315

Group type: EXPERIMENTAL
Intervention: Various treatments for non-specific low back pain
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Treatments with large effects (>20 points)
Number of subjects: 76
Study: 17890232

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart twice daily
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Prandial insulin aspart three times daily
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Basal insulin detemir once daily (twice if required)
Number of subjects: 708
Study: 15530130

Group type: EXPERIMENTAL
Intervention: Loperamide 16mg with Saquinavir 600mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saquinavir 600mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Loperamide 16mg
Number of subjects: 12
Study: 11682378

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.7%‐1.8%)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Esmolol (105 g x kg(‐1) x min(‐1)) and Nitroglycerin (1‐6 mg/h)
Number of subjects: 16
Study: 7938293

Group type: EXPERIMENTAL
Intervention: Endoscopic median nerve decompression (two-portal Chow technique)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open median nerve decompression (Taleisnik technique)
Number of subjects: 40
Study: 3365858

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 29395965

Group type: EXPERIMENTAL
Intervention: 4 mg emedastine patch
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: 8 mg emedastine patch
Number of subjects: 1276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg tablet)
Number of subjects: 1276
Study: 26343421

Group type: EXPERIMENTAL
Intervention: ProTaper Next
Number of subjects: 30

Group type: COMPARATOR
Intervention: ProTaper Universal (PTU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both instruments
Number of subjects: 30
Study: 25372846

Group type: EXPERIMENTAL
Intervention: Risperidone or aripiprazole (12 weeks treatment)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 24
Study: 23159393

Group type: EXPERIMENTAL
Intervention: Transanal endoscopic microsurgery (TEMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic lower anterior resection (LAR)
Number of subjects: 60
Study: 21575026

Group type: EXPERIMENTAL
Intervention: Oct‐LAR
Number of subjects: 22

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 22
Study: 18291251

Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal hernia repair (TEP)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Open tension-free repair (Lichtenstein repair)
Number of subjects: 168
Study: 16219797

Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide (FC)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Fludarabine alone
Number of subjects: 375
Study: 14623504

Group type: EXPERIMENTAL
Intervention: CQI group with peer review topics including 'airway aspiration' and 'measuring blood pressure'
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group with peer review topics including 'perineal repair' and 'artificial rupture of the membranes (ARM)'
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: CQI group with peer review topics including 'perineal repair'
Number of subjects: 255
Study: 10890457

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 13
Study: 9312922

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA) 5.2 g daily for 12 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA)
Number of subjects: 55
Study: 8513986

Group type: EXPERIMENTAL
Intervention: Metoclopramide with methysergide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoclopramide with metergoline or pizotifen
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoclopramide with fluoxetine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 6
Study: 2880066

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 500 mg, three times a day for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous azlocillin 5 g and gentamicin 80 mg, three times a day for 10 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 40
Study: 31628272

Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Scale (PCS) scores at 6 months post-ACLR
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Scale (PCS) scores at various time points
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Preoperative PCS scores
Number of subjects: 48
Study: 28368955

Group type: EXPERIMENTAL
Intervention: CHO + PRO
Number of subjects: 21

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 21
Study: 27237081

Group type: EXPERIMENTAL
Intervention: Training and support (TS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Financial reimbursement (FR)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Training and support (TS) plus Financial reimbursement (FR)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Training and support (TS) plus Financial reimbursement (FR) plus eBI
Number of subjects: 120

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Referral to eBI
Number of subjects: 120
Study: 25706053

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo-KT
Number of subjects: 46
Study: 23801606

Group type: EXPERIMENTAL
Intervention: Immediate Switch (IS) to raltegravir
Number of subjects: 164

Group type: COMPARATOR
Intervention: Deferred Switch (DS) to raltegravir at week 24
Number of subjects: 164
Study: 21083623

Group type: EXPERIMENTAL
Intervention: CPP‐ACFP paste
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control paste
Number of subjects: 54
Study: 18502772

Group type: EXPERIMENTAL
Intervention: Orthonasal stimulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Retronasal stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of stimulation routes
Number of subjects: 30
Study: 16421364

Group type: EXPERIMENTAL
Intervention: 7 percent hypertonic saline
Number of subjects: 164

Group type: COMPARATOR
Intervention: 0.9 percent saline (control)
Number of subjects: 164
Study: 14656276

Group type: EXPERIMENTAL
Intervention: TEC (paclitaxel 175 mg/m2, carboplatin AUC 5, epirubicin 75 mg/m2)
Number of subjects: 887

Group type: COMPARATOR
Intervention: TC (paclitaxel 175 mg/m2, carboplatin AUC 5)
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: TEC
Number of subjects: 887
Study: 10843145

Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemic clamp (3 mU/kg x min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9002786

Group type: EXPERIMENTAL
Intervention: Braun Plak Remover (D7)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Modified Plak Control (D9)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sonicare
Number of subjects: 49
Study: 8402762

Group type: EXPERIMENTAL
Intervention: Celiprolol (300 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3805311

Group type: EXPERIMENTAL
Intervention: Paradoxical intention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31960175

Group type: EXPERIMENTAL
Intervention: Exposure-based SAD-specific group cognitive behavioral therapy (CBT), n=31
Number of subjects: 67

Group type: COMPARATOR
Intervention: Waitlist control (WLC), n=36
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: CBT group
Number of subjects: 67
Study: 30367021

Group type: EXPERIMENTAL
Intervention: Electrocardiography and 2-dimensional echocardiography
Number of subjects: 60
Study: 27737602

Group type: EXPERIMENTAL
Intervention: Exercise Group (ExG) - 16-week exercise training program combining aerobic activities and resistance training
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exercise Group (ExG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 32
Study: 24281236

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily at bedtime
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 20216118

Group type: EXPERIMENTAL
Intervention: Azathioprine therapy
Number of subjects: 37
Study: 18380934

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation programme (n = 52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Clinic-based rehabilitation programme (n = 52)
Number of subjects: 104
Study: 15984576

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: No thrombolytic therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Beta-adrenoblockers (administered in both groups)
Number of subjects: 64
Study: 12753444

Group type: EXPERIMENTAL
Intervention: Epidural infusion of morphine (40 micro g x kg‐1 initial bolus, 10 micro g.ml‐1 infusion)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Epidural infusion of clonidine (1 micro g x kg‐1 initial bolus, 0.6 micro g.ml‐1 infusion)
Number of subjects: 26
Study: 10069510

Group type: EXPERIMENTAL
Intervention: Tiotropium (once daily inhalation for 28 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium (protection against methacholine challenge)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium (compared to baseline)
Number of subjects: 0
Study: 8913544

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg once daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Losartan with low-dose hydrochlorothiazide
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 1857312

Group type: EXPERIMENTAL
Intervention: Dental prosthesis (Snore‐No‐More) worn on experimental nights
Number of subjects: 14

Group type: COMPARATOR
Intervention: No device worn on control nights
Number of subjects: 14
Study: 6298934

Group type: EXPERIMENTAL
Intervention: Single oral dose of cotrimoxazole
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Single oral dose of amoxycillin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Oral dose of Na-bicarbonate
Number of subjects: 68
Study: 30203839

Group type: EXPERIMENTAL
Intervention: Siltuximab (anti-IL6 monoclonal antibody)
Number of subjects: 38
Study: 29851741

Group type: EXPERIMENTAL
Intervention: 8-week multicomponent intervention (n=48)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 89
Study: 26067580

Group type: EXPERIMENTAL
Intervention: Reaching training group (n = 15) received 3 sessions of training by a physical therapist
Number of subjects: 30

Group type: COMPARATOR
Intervention: Social control group (n = 15) received a similar amount of time sitting in the therapist's lap
Number of subjects: 30
Study: 23336746

Group type: EXPERIMENTAL
Intervention: Tretinoin cream (0.05%) and Aloe vera topical gel (50%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tretinoin cream (0.05%) and vehicle
Number of subjects: 60
Study: 22250951

Group type: EXPERIMENTAL
Intervention: Intracranial stent placement with Gateway balloon and Wingspan self‐expanding nitinol stent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracranial angioplasty and stent placement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Credentialing process for interventionalists
Number of subjects: 0
Study: 20938821

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic reflux correction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surveillance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open operative reflux therapy
Number of subjects: 0
Study: 18547426

Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 6 mg Si
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 12 mg Si
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 3 mg Si
Number of subjects: 136

Group type: COMPARATOR
Intervention: Calcium and Vitamin D3 (Ca/Vit D3) alone
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 6 mg Si (subgroup analysis)
Number of subjects: 136
Study: 15947831

Group type: EXPERIMENTAL
Intervention: 10% polyvinylpyrrolidone-iodine solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.9% physiological saline solution
Number of subjects: 30
Study: 12199971

Group type: EXPERIMENTAL
Intervention: Pressurized metered-dose inhalers (MDIs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dry powder inhalers (DPIs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Turbuhaler (DPI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 10
Study: 10424324

Group type: COMPARATOR
Intervention: Desmopressin alone (reference)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg at -24, -12 h and -1 h)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg q.i.d, first dose 3 days before study)
Number of subjects: 18
Study: 8524984

Group type: EXPERIMENTAL
Intervention: ipsapirone (0.3 mg per kg body weight)
Number of subjects: 30
Study: 2273527

Group type: EXPERIMENTAL
Intervention: Nicotine (1.0 mg FTC‐estimated nicotine delivery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nicotine-free cigarette
Number of subjects: 30
Study: 7006783

Group type: EXPERIMENTAL
Intervention: Different types of therapy for five types of glomerulonephritis (specific therapies not detailed in the abstract)
Number of subjects: 0
Study: 31879033

Group type: EXPERIMENTAL
Intervention: SYDNEY device (1 × 300 mg injection)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Currently approved autoinjector (2 × 150 mg injections)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: SYDNEY device
Number of subjects: 69

Group type: COMPARATOR
Intervention: Currently approved autoinjector
Number of subjects: 69
Study: 30531304

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: m.10398G mtDNA variant
Number of subjects: 37
Study: 27005768

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 25935581

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 4038
Study: 24085466

Group type: EXPERIMENTAL
Intervention: PICSI (sperm selected based on ability to bind to hyaluronic acid)
Number of subjects: 156

Group type: COMPARATOR
Intervention: ICSI (sperm selected based on visual assessment)
Number of subjects: 156
Study: 20934265

Group type: EXPERIMENTAL
Intervention: Combined modality treatment (CMT) using radiotherapy (RT), infusional 5‐fluorouracil, and mitomycin C
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) boost (15 Gy)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Iridium-192 implant boost (25 Gy)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Boosted patients
Number of subjects: 577

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 577
Study: 19106078

Group type: EXPERIMENTAL
Intervention: Implementation intentions specifying motivational cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implementation intentions specifying situational cues
Number of subjects: 0
Study: 17364418

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Substance Abuse Domestic Violence (SADV) group
Number of subjects: 85

Group type: COMPARATOR
Intervention: Twelve-Step Facilitation (TSF) Group
Number of subjects: 85
Study: 15188832

Group type: EXPERIMENTAL
Intervention: 200 mg danazol three times daily for 6 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprorelin acetate depot every 28 days for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (women without pelvic disease)
Number of subjects: 100
Study: 11469429

Group type: EXPERIMENTAL
Intervention: Isoproterenol test (20 patients)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Nitroglycerin test (23 patients)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Nitroglycerin test (positive group)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Isoproterenol test (positive group)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 133

Group type: COMPARATOR
Intervention: Negative response group
Number of subjects: 133
Study: 9521833

Group type: EXPERIMENTAL
Intervention: Nightcap sleep monitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Awakenings after 15 s to 5 min of sleep
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep-onset reports
Number of subjects: 0
Study: 8110557

Group type: EXPERIMENTAL
Intervention: dobutamine 10 micrograms kg‐1 min‐1 before discontinuation of CPB
Number of subjects: 28

Group type: COMPARATOR
Intervention: enoximone 0.5 mg kg‐1 followed by an infusion of 10 micrograms kg‐1 min‐1 before discontinuation of CPB
Number of subjects: 28
Study: 2922790

Group type: EXPERIMENTAL
Intervention: Neocyte-enriched RBCs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control RBCs of all ages
Number of subjects: 0
Study: 20034163

Group type: EXPERIMENTAL
Intervention: Secobarbital
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One second estimation schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ten second estimation schedule
Number of subjects: 0
Study: 30876959

Group type: EXPERIMENTAL
Intervention: 2-step approach using NAFLD fibrosis score (NFS) followed by liver stiffness measurement (LSM) for patients with indeterminate or high NFS
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: 2-step approach using NAFLD fibrosis score (NFS) followed by LSM
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: LSM ≥10 kPa alone for diagnosis of advanced fibrosis
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Fibrosis-4 score
Number of subjects: 759
Study: 28320794

Group type: EXPERIMENTAL
Intervention: Community health volunteers (CHVs) offering free rapid diagnostic tests (RDTs) and vouchers for WHO-qualified artemisinin combination therapy (ACT) at a reduced price.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study: 26143613

Group type: EXPERIMENTAL
Intervention: Lyophilized-SC
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Liquid-SC
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Liquid-ID
Number of subjects: 524
Study: 23551657

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg twice a day for 14 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (standard medical treatment for ICH)
Number of subjects: 44